University of California San Francisco

Emily Bergsland, MD

Emily Bergsland, M.D.
Emily Bergsland, MD

Professor of Clinical Medicine
Division of Hematology Oncology
Department of Medicine
Ernest Rosenbaum, MD Endowed Chair of Medical Oncology

Address

550 16th Street, #6804
San Francisco, CA 94158
United States

Email: [email protected]

Biography

Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2019
University of California (UCSF) Molecular Medicine Training Program 06/1998
University of California (UCSF) Fellowship Medical Oncology 06/1995
University of California (UCSF) Chief Residency 06/1993
University of California (UCSF) Residency Internal Medicine 06/1992
University of Minnesota MD Medicine 06/1989
University of Wisconsin BS Biochemistry/Molecular Biology 05/1985

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty

Clinical Expertise

Colon Cancer
Esophageal Cancer
Liver Cancer
Lynch Syndrome
Pancreatic Cancer
Rectal Cancer
Stomach Cancer

Clinical Trials

  1. Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors (NCT05746208)
    Related Conditions: Neuroendocrine Tumor, Neuroendocrine Carcinoma| Start Date: | End Date:
  2. Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (NCT05746182)
    Related Conditions: Pancreatic Neuroendocrine Neoplasm| Start Date: | End Date:
  3. Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas (NCT03136055)
    Related Conditions: Neuroendocrine Carcinoma| Start Date: | End Date:
  4. RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (NCT00843531)
    Related Conditions: Neuroendocrine Tumor, Carcinoid Tumor, Glioma, Pheochromocytoma| Start Date: | End Date:
  5. Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (NCT00227617)
    Related Conditions: Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor, Lung Tumor, Neoplasms| Start Date: | End Date:
  6. Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors (NCT00390156)
    Related Conditions: Solid Tumor| Start Date: | End Date:

Grants and Funding

  • UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology | NIH | 2021-07-01 - 2026-06-30 | Role: Principal Investigator

Research Interests

Angiogenesis Inhibitors 
Pancreatic Neoplasms 
Vascular Endothelial Growth Factor
Colorectal Neoplasms 
Neuroendocrine Tumors 

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 100
  1. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy.
    Moradpour M, Moradi Tochayi A, Houshmand S, Nwihim S, Jiang F, Yadav S, Lindsay S, Bergsland EK, Hope TA| | PubMed
  2. Characterization of small intestinal neuroendocrine tumorlets.
    Yogo A, Akanuma N, Kim GE, Paciorek A, Zhang L, Le P, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  3. ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.
    Expert Panel on Gastrointestinal Imaging, Yacoub JH, Yano M, Chang KJ, Bergsland E, Bhosale PR, Cash BD, Chernyak V, Gupta A, Hallet J, Halpern J, Magnetta M, Noronha CF, Refaat T, Korngold EK| | PubMed
  4. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.
    Choucair A, Zdunek A, Liao M, Bodei L, Deandreis D, Das J, Barbe R, Bergsland E, Geyer S, Bidault F, Garcia G, Yeh R, Balleyguier C, Lassau N, Dercle L, Ammari S| | PubMed
  5. Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
    de Mestier L, Halfdanarson TR, Apostolidis L, Koumarianou A, Hernando J, Riechelmann R, Bergsland EK, Cingarlini S, Shaheen S, Crona J, Kreutzfeldt S, Mosalem O, Al-Toubah T, Cros J, Strosberg JR| | PubMed
  6. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
    Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA| | PubMed
  7. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning.
    Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE| | PubMed
  8. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study.
    Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, Felismino TC, Knappskog S, Trevizani E, Cingarlini S, Sorbye H| | PubMed
  9. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms.
    Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies Consortium Group| | PubMed
  10. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.
    Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies (PSM) Consortium Group| | PubMed
  11. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK| | PubMed
  12. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus.
    Casey M, Tozzi F, Wang J, Park KM, Bergsland E, Hope T, Kennecke HF, Rose JB, Babicky M, Irani SS, El-Hayek KM, Hilal MA, Asbun HJ, Cleary S, Smeets P, Berrevoet F, Adam M, Rashidian N, Alseidi A, PNET Diagnosis Research Group| | PubMed
  13. Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study.
    Hong CW, Yang Y, Remick I, Su P, Itriago-Leon P, Nickel MD, Fautz HP, Majeed W, Bergsland E, Hope TA, Ohliger MA| | PubMed
  14. Metastatic insulinoma-outcomes in the current era.
    Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E| | PubMed
  15. Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling.
    Paciorek A, Mulvey C, McKinley M, Zhang L, Cheng I, Moon F, Le BK, Shih BE, Whitman J, Bergsland E| | PubMed
  16. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK| | PubMed
  17. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
    Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S| | PubMed
  18. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
    Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN| | PubMed
  19. Withdrawal pain following patients discontinuing Trk inhibitors.
    Chin A, Lindsay S, Bergsland EK, Kang H| | PubMed
  20. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR| | PubMed
  21. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
    Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P| | PubMed
  22. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  23. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
    Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C| | PubMed
  24. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K| | PubMed
  25. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
    Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA| | PubMed
  26. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
    Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I| | PubMed
  27. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.
    Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH, Habra MA, Bancos I, McKenzie TJ| | PubMed
  28. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK| | PubMed
  29. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
    Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants| | PubMed
  30. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow.
    Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S| | PubMed
  31. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.
    Varghese DG, Del Rivero J, Bergsland E| | PubMed
  32. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA| | PubMed
  33. Preclinical Models of Adrenocortical Cancer.
    Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J| | PubMed
  34. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
    Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK| | PubMed
  35. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK| | PubMed
  36. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
    Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR| | PubMed
  37. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
    Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A| | PubMed
  38. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, Hale G, Shafizadeh N, Cho SJ, Whitman J, Gill RM, Jones KD, Navale P, Bergsland E, Klimstra D, Joseph NM| | PubMed
  39. Preclinical Models of Neuroendocrine Neoplasia.
    Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J| | PubMed
  40. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M| | PubMed
  41. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
    Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN| | PubMed
  42. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
    Sun F, Grenert JP, Tan L, Van Ziffle J, Joseph NM, Mulvey CK, Bergsland E| | PubMed
  43. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
    Hope TA, Pavel M, Bergsland EK| | PubMed
  44. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.
    Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M| | PubMed
  45. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA| | PubMed
  46. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
    Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP| | PubMed
  47. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S| | PubMed
  48. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S| | PubMed
  49. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C| | PubMed
  50. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M| | PubMed
  51. The Immunotherapy Landscape in Adrenocortical Cancer.
    Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J| | PubMed
  52. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
    Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH| | PubMed
  53. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K| | PubMed
  54. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK| | PubMed
  55. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms.
    Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S| | PubMed
  56. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
    Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M| | PubMed
  57. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
    Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA| | PubMed
  58. Carcinoid Crisis-Induced Acute Systolic Heart Failure.
    Maddali MV, Chiu C, Cedarbaum ER, Yogeswaran V, Seedahmed M, Smith W, Bergsland E, Fidelman N, Kennedy JLW| | PubMed
  59. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
    Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC| | PubMed
  60. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
    Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA| | PubMed
  61. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of
    Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E| | PubMed
  62. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
    Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR| | PubMed
  63. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
    Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K| | PubMed
  64. Reply to S. Boutayeb et al.
    Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY| | PubMed
  65. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.
    Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA| | PubMed
  66. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.
    Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY| | PubMed
  67. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
    Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA| | PubMed
  68. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  69. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
    Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J| | PubMed
  70. A Rare Case of Carcinoid Constrictive Pericarditis.
    Wang TS, Bergsland EK, Zhang R, Ihnken K, Tolstrup K| | PubMed
  71. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  72. Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
    Whitman J, Kardosh A, Diaz L, Fong L, Hope T, Onodera C, Joseph N, Le D, Fisher G, Bergsland E| | PubMed
  73. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K| | PubMed
  74. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
    Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P| | PubMed
  75. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  76. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
    Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA| | PubMed
  77. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  78. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N| | PubMed
  79. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K| | PubMed
  80. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
    Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W| | PubMed
  81. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  82. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH| | PubMed
  83. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK| | PubMed
  84. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
    Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E, Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group| | PubMed
  85. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  86. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM| | PubMed
  87. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.
    Mulvey CK, Bergsland EK| | PubMed
  88. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
    Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G| | PubMed
  89. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
    Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH| | PubMed
  90. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
    Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB| | PubMed
  91. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
    Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR| | PubMed
  92. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.
    Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP| | PubMed
  93. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
    Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK| | PubMed
  94. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF| | PubMed
  95. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
    Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK| | PubMed
  96. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
    Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E| | PubMed
  97. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA| | PubMed
  98. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK| | PubMed
  99. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP| | PubMed
  100. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
    Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK| | PubMed